Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

12:05pm EDT
Price Change (% chg)

-40.00p (-2.41%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for HIK.L


Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates in three business segments: Branded, Injectables, and Generics. The majority of its operations are... (more)


Beta: 0.84
Market Cap (Mil.): £3,287.58
Shares Outstanding (Mil.): 198.53
Dividend: 4.20
Yield (%): 0.72


  HIK.L Industry Sector
P/E (TTM): 17.41 32.64 33.50
EPS (TTM): 0.95 -- --
ROI: 23.44 18.10 17.33
ROE: 30.29 18.80 18.19
Search Stocks

UPDATE 2-Hikma Pharma cuts revenue forecast for branded drugs

* Revenue in injectibles business rises 41 pct to $346 mln

20 Aug 2014

Hikma first-half profit jumps on strong injectibles sales

Aug 20 - Hikma Pharmaceuticals Plc reported a 44 percent rise in first-half adjusted profit, helped by strong demand for its high-margin injectibles particularly in the United States.

20 Aug 2014

BRIEF-Hikma Pharma to buy Ben Venue's generic injectables factory

* Agreed with Ben Venue Laboratories, Inc. , part of Boehringer Ingelheim Group of companies, to acquire their generic injectables manufacturing site in Bedford, Ohio

24 Jul 2014

Emerging market fund managers ignore borders, chase profits

BOSTON - U.S. emerging market fund managers are paying less attention to where a company is located or listed than to whether it's making money, either as an advanced world company doing business in the developing world, or the other way around.

10 Jul 2014

BRIEF-Hikma buys assets of Bedford Laboratories for $300 mln

* Signed an asset purchase agreement with Ben Venue Laboratories Inc., a member of Boehringer Ingelheim Group of Companies

28 May 2014

BRIEF-Hikma raises operating margin forecast for injectables unit

* Has made a strong start to year and pleased to be reiterating guidance for 2014 of around 5 pct group revenue growth

15 May 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Provider: Peel Hunt
Provider: Peel Hunt
Provider: Thomson Reuters StreetEvents

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks